All In Biotech

Drug Trial Radar · NCT05691517

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

Pilot Study of CBX-12 Pharmacodynamics in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Jun 12, 2024

Primary completion

Oct 15, 2028

Study completion Oct 15, 2028

Sponsor

Sponsor type
NIH
First posted
Jan 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies how well CBX-12 works in treating patients with solid tumors that have spread from where they first started (primary site) to started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or other places in the body (metastatic). CBX-12 works by binding to a protein called TOP1 that is present inside the cells. This allows CBX-12 to kill the cancer cells by damaging their DNA, resulting in cancer cell death. This trial is being done to find out if this approach is better or worse than the usual approach for advanced cancers.

Conditions

  • Advanced Malignant Solid Neoplasm
  • Metastatic Malignant Solid Neoplasm

Interventions

  • Biopsy ProcedureProcedure

    Undergo tumor biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT scan

  • pH Low Insertion Peptide-exatecan Conjugate CBX-12Drug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early Rad51/deoxyribonucleic acid (DNA) damage response (DDR)Time frame: At cycle 1 day 2 (1 cycle = 28 days)
  2. Late Rad51/DDR responseTime frame: At cycle 3 day 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Cancer Institute Developmental Therapeutics Clinic

    Bethesda, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.